# Article information:

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy - PMC  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994406/>

# Article summary:

1. Rituximab is a chimeric mouse/human monoclonal antibody therapy with binding specificity to CD20, and was the first therapeutic antibody approved for oncology patients.

2. Polymorphisms in Fc gamma receptor and complement protein genes have been implicated as potential predictors of differential response to rituximab, but have not yet shown sufficient influence to impact clinical decisions.

3. Two new anti-CD20 antibodies have been approved since rituximab, and biosimilars are becoming available as its patent expires.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article “Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy” provides an overview of the current research into mechanisms and potential biomarkers of rituximab response, as well as its biosimilars and the newer CD20 binding mAb therapies. The article is written from a scientific perspective and provides a comprehensive overview of the current state of research into rituximab therapy. It is well-referenced with numerous studies cited throughout the text, providing evidence for the claims made in the article. The article does not appear to be biased or one-sided in its reporting; it presents both sides equally by discussing both successes and challenges associated with rituximab therapy. Furthermore, it does not appear to contain any promotional content or partiality towards any particular product or company. The article does note possible risks associated with rituximab therapy, such as adverse effects that can occur due to its use. In conclusion, this article appears to be trustworthy and reliable in terms of its content and presentation of information regarding rituximab therapy.

# Topics for further research:

* Rituximab biomarkers
* Rituximab biosimilars
* CD20 binding mAb therapies
* Rituximab adverse effects
* Rituximab clinical trials
* Rituximab mechanism of action

# Report location:

<https://www.fullpicture.app/item/bfba0999b41836d0349a24337c54642e>